mTORC1 (Mechanistic Target of Rapamycin Complex 1) is a central regulator of cell growth, metabolism, and autophagy. It integrates signals from nutrients, growth factors, energy status, and stress to control protein synthesis, lipid metabolism, and autophagy. mTORC1 hyperactivity is a hallmark of Alzheimer's disease and other neurodegenerative disorders, contributing to synaptic dysfunction, protein aggregate accumulation, and neuronal death.
mTORC1 is a ~1 kDa protein complex containing: (1) mTOR (the catalytic subunit, a serine/threonine kinase); (2) Raptor (regulatory protein associated with mTOR); (3) mLST8 (also called GβL); (4) PRAS40 and Deptor (inhibitory subunits). mTOR contains a HEAT repeat region, FAT domain, FRB domain (rapamycin binding), kinase domain, and FATC domain. mTORC1 localizes to the lysosomal surface where it is activated by amino acids and growth factors.
mTORC1 is a master regulator of anabolism and catabolism. Key functions: (1) Activates S6K1 to phosphorylate ribosomal protein S6, enhancing translation of 5'TOP mRNAs; (2) Phosphorylates 4E-BP1 to release eIF4E, promoting cap-dependent translation; (3) Inhibits autophagy by phosphorylating ULK1 complex and Atg14L; (4) Activates lipid synthesis through SREBP; (5) Inhibits lysosome biogenesis through TFEB phosphorylation. mTORC1 integrates inputs from insulin/IGF, amino acids, ATP, and oxygen.
mTORC1 hyperactivity is strongly implicated in Alzheimer's disease: (1) Aβ and tau pathology activate mTORC1 signaling; (2) mTORC1 overactivity impairs autophagy, leading to protein aggregate accumulation; (3) Hyperactive mTORC1 suppresses synaptic plasticity and memory formation; (4) mTORC1 drives tau phosphorylation through S6K1. In Parkinson's disease, mTORC1 dysregulation affects alpha-synuclein clearance. mTORC1 inhibitors (rapamycin, everolimus) show beneficial effects in AD models.
mTORC1 inhibitors (rapamycin, rapalogs) are FDA-approved for transplant rejection and cancer. In neurodegeneration: (1) Rapamycin enhances autophagy and clears Aβ and tau in mouse models; (2) mTOR inhibition improves memory in AD models; (3) Challenges include immunosuppression and metabolic side effects. Novel approaches include: partial mTOR inhibitors, autophagy enhancers that bypass mTOR, and brain-penetrant rapamycin analogs.